

Based on a review of the information collection since our last request for OMB approval, we have made adjustments to our burden estimate to account for advances in information and communication technology that have occurred in the last decade. Because the transition from paper-based to electronic records systems is widespread, we estimate that the average burden per recordkeeping has decreased by 50 percent. With regards to records maintenance, we estimate that approximately 379,493 facilities each spend half the amount of time from the 13,228 hours previously reported to 6.61 hours collecting, recording, and checking for accuracy of the limited amount of additional information required by the regulations, for a total of 2,508,449 hours annually. In addition, we estimate that new firms entering the affected businesses incur a burden from learning the regulatory requirements and understanding the records required for compliance. In this regard, we estimate the number of new firms entering the affected businesses is 5 percent of 379,493, or 18,975 firms. Thus, we estimate that approximately 18,975 facilities each spend, on average, 4.5 hours learning about the recordkeeping and records access requirements, for a total of 85,388 hours annually. This estimate reflects a reduction from 4.79 to 4.5 average hours per facility to account for the increase in facilities using internet, which increased from 71 to 99 percent. We estimate that approximately the same number of firms (18,975) exit the group of affected businesses in any given year, resulting in no growth in the number of total firms reported on line 1 of table 1.

Dated: April 1, 2020.

**Lowell J. Schiller,**

*Principal Associate Commissioner for Policy.*

[FR Doc. 2020-07275 Filed 4-6-20; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2020-N-0626]

#### Pulmonary-Allergy Drugs Advisory Committee; Postponed

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The meeting of the Pulmonary-Allergy Drugs Advisory Committee (PADAC) scheduled for April 21, 2020, is postponed. The Food

and Drug Administration (FDA), like other government agencies, is taking the necessary steps to ensure the Agency is prepared to continue our vital public health mission in the event that our day-to-day operations are impacted by the COVID-19 public health emergency. Therefore, we are canceling or postponing all non-essential meetings through the month of April. We will reassess on an ongoing basis for future months. Therefore, this meeting is being postponed. The meeting was announced in the **Federal Register** on February 20, 2020.

#### FOR FURTHER INFORMATION CONTACT:

LaToya Bonner, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, Fax: 301-847-8533, email: [PADAC@fda.hhs.gov](mailto:PADAC@fda.hhs.gov), or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), and follow the prompts to the desired center or product area. Please call the Information Line for up-to-date information on this meeting, which was announced in the **Federal Register** of February 20, 2020 (85 FR 9780).

Dated: April 1, 2020.

**Lowell J. Schiller,**

*Principal Associate Commissioner for Policy.*

[FR Doc. 2020-07262 Filed 4-6-20; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2019-N-5550]

#### Elite Laboratories, Inc., et al.; Withdrawal of Approval of 23 Abbreviated New Drug Applications; Correction

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; correction.

**SUMMARY:** The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** on January 8, 2020. The document announced the withdrawal of approval of 23 abbreviated new drug applications (ANDAs) from multiple applicants, withdrawn as of February 7, 2020. The document indicated that FDA was withdrawing approval of the following seven ANDAs after receiving a withdrawal request from CASI Pharmaceuticals, Inc., c/o Target Health, Inc., 261 Madison Ave., 24th Floor, New

York, NY 10016: ANDA 073191, Triamterene and Hydrochlorothiazide Capsules USP, 50 milligrams (mg)/25 mg; ANDA 076075, Econazole Nitrate Cream, 1%; ANDA 076192, Ribavirin Capsules USP, 200 mg; ANDA 076514, Midodrine Hydrochloride (HCl) Tablets USP, 2.5 mg, 5 mg, and 10 mg; ANDA 086809, Spironolactone Tablets USP, 25 mg; ANDA 090288, Naratriptan Tablets USP, Equivalent to (EQ) 1 mg base and EQ 2.5 mg base; and ANDA 203384, Epinastine HCl Ophthalmic Solution, 0.05%. Before FDA withdrew the approval of these ANDAs, CASI Pharmaceuticals, Inc., informed FDA that it did not want the approval of the ANDAs withdrawn. Because CASI Pharmaceuticals, Inc., timely requested that approval of these ANDAs not be withdrawn, the approval of ANDAs 073191, 076075, 076192, 076514, 086809, 090288, and 203384 is still in effect.

#### FOR FURTHER INFORMATION CONTACT:

Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 240-402-6980, [Martha.Nguyen@fda.hhs.gov](mailto:Martha.Nguyen@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of Wednesday, January 8, 2020 (85 FR 909), in FR Doc. 2020-00076, on page 909, the following correction is made:

1. On pages 909 and 910, in the table, the entries for ANDAs 073191, 076075, 076192, 076514, 086809, 090288, and 203384 are removed.

Dated: April 1, 2020.

**Lowell J. Schiller,**

*Principal Associate Commissioner for Policy.*

[FR Doc. 2020-07265 Filed 4-6-20; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Ryan White HIV/AIDS Program Part F; AIDS Education and Training Centers; National HIV Curriculum e-Learning Platform; Technology Operations and Maintenance Project

**AGENCY:** Health Resources and Services Administration (HRSA), Department of Health and Human Services.

**ACTION:** Notice of supplemental award.

**SUMMARY:** HRSA's HIV/AIDS Bureau will award \$100,000 in supplemental funding to the University of Washington to support the AIDS Education and Training Centers' (AETC) National HIV

Curriculum (NHC) e-Learning Platform: Technology Operations and Maintenance project in Fiscal Year (FY) 2020 and, pending the availability of funds, in each succeeding year of the project's period of performance. This supplemental funding will enable the recipient to implement technological enhancements to the NHC eLearning Platform to increase access and improve efficiency of new online training modules and learning activities that respond to specific needs, as identified, by Ending the HIV Epidemic: A Plan for America (EHE) initiative jurisdictions. These system enhancements will help increase the number of health professionals that have access to state of the art HIV treatment interventions and protocols.

**FOR FURTHER INFORMATION CONTACT:**

Sherrilyn Crooks, Chief, HIV Education Branch, Office of Training and Capacity Development, HRSA, 5600 Fishers Lane, Room 9N110, Rockville, MD 20857, by email at [scrooks@hrsa.gov](mailto:scrooks@hrsa.gov) or by phone at (301) 443-7662.

**SUPPLEMENTARY INFORMATION:**

*Intended Recipient of the Award:* The University of Washington, AIDS Education and Training.

*Centers National HIV Curriculum e-Learning Platform:* Technology Operations and Maintenance project.

*Amount of Award:* \$100,000 is available in FY 2020.

*Project Period:* March 1, 2020–August 31, 2022.

*CFDA Number:* 93.145.

*Authority:* 42 U.S.C. 300ff–111(a) (section 2692(a) of the Public Health Service (PHS) Act), 42 U.S.C. 300ff–121 (section 2693 of the PHS Act), and Further Consolidated Appropriations Act, 2020 (Pub. L. 116–94).

*Justification:* The University of Washington currently manages the e-Learning platform, which hosts the AETC's web-based NHC. The NHC e-Learning Platform provides state of the art HIV care training and resources to providers nation-wide. With additional supplemental funding, the University of Washington will strengthen the existing capacity of the e-Learning platform to ensure that additional, up-to-date HIV treatment resources and information are available, with a special focus on jurisdictions targeted by the EHE initiative.

The supplemental award will enable the recipient to leverage its existing infrastructure to meet the learning needs of the HIV workforce in EHE designated areas. The recipient will be able to enhance and maintain an e-Learning Platform that provides a valuable and accessible tool designed to strengthen

the skills and knowledge base of professionals that care for people with or at risk for HIV. In addition, supplemental funding will allow this recipient to ensure that providers in EHE target areas are aware of the National HIV Curriculum and know how to access and use it. Expanding the availability of state-of-the-art HIV care and treatment training resources will help prepare for the projected increase in demand for well-trained HIV care professionals as a result of the EHE rollout. This award recipient has the demonstrated expertise and scalable experience required to swiftly address these time-sensitive training and technical assistance needs.

**Thomas J. Engels,**

*Administrator.*

[FR Doc. 2020–07314 Filed 4–6–20; 8:45 am]

**BILLING CODE 4165–15–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Rescheduling National Advisory Council on Migrant Health Meeting

**AGENCY:** Health Resources and Services Administration (HRSA); Department of Health and Human Services (HHS).

**ACTION:** Notice; correction.

**SUMMARY:** This is to notify the public that the National Advisory Council on Migrant Health (NACMH) meeting, originally scheduled for May 5–6, 2020, is re-scheduled to July 29–30, 2020. The May 5–6, 2020, NACMH meeting was announced in the *Federal Register*, Vol. 85, No. 41, on Monday, March 2, 2020 (FR Doc. 2020–04169 Filed 2–28–20). The decision to re-schedule the NACMH meeting has been made after carefully examining the Centers for Disease Control and Prevention's recommendations to restrict all non-essential travel, and the widespread health risks posed by COVID–19 to the American public. The location and agenda for the re-scheduled NACMH meeting remains as posted in the *Federal Register*, Vol. 85, No. 41, on Monday, March 2, 2020. For calendar year 2020 meetings, agenda items may include, but are not limited to, topics and issues related to migratory and seasonal agricultural worker health. Refer to the NACMH website listed below for all current and updated information concerning the calendar year 2020 NACMH meetings, including draft agendas and meeting materials,

which will be posted 30 calendar days before the meeting.

**DATES:** July 29–30, 2020; 9:00 a.m. to 5:00 p.m. Mountain Time (MT).

**ADDRESSES:** The meeting will be held in-person at Courtyard Boulder Longmont, 1410 Dry Creek Drive, Longmont, Colorado 80503.

Instructions for joining the meeting in-person will be posted on the NACMH website 30 business days before the date of the meeting. For meeting information updates, go to the NACMH website at: <https://bphc.hrsa.gov/qualityimprovement/strategicpartnerships/nacmh/index.html>.

**FOR FURTHER INFORMATION CONTACT:**

Esther Paul, NACMH Designated Federal Officer (DFO), Strategic Initiatives and Planning Division, Office of Policy and Program Development, Bureau of Primary Health Care, HRSA, 5600 Fishers Lane, Rockville, Maryland 20857; 301–594–4300; or [epaul@hrsa.gov](mailto:epaul@hrsa.gov).

*Correction: The NACMH meeting originally scheduled to take place on May 5–6, 2020, is re-scheduled to July 29–30, 2020.*

**Maria G. Button,**

*Director, Executive Secretariat.*

[FR Doc. 2020–07204 Filed 4–6–20; 8:45 am]

**BILLING CODE 4165–15–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Ryan White HIV/AIDS Program Part F Regional AIDS Education and Training Centers

**AGENCY:** Health Resources and Services Administration (HRSA), Department of Health and Human Services.

**ACTION:** Notice of supplemental award.

**SUMMARY:** HRSA's HIV/AIDS Bureau will award supplemental funding to the eight current recipients of the Ryan White HIV/AIDS Program Part F Regional AIDS Education and Training Centers (AETC) in Fiscal Year (FY) 2020 and pending the availability of funds, in each succeeding fiscal year of their periods of performance. The recipients will use this supplement funding to provide critical expertise and resources to respond to the specific workforce development needs of novice and experienced health professionals who care for people with or at risk for HIV in Ending the HIV Epidemic focus areas.